Compare Cytokinetics Inc (CYTK) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.18. The key difference: Cytokinetics Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | VCIT | |
|---|---|---|
Market Cap | $10.78B | — |
Sector | Technology | Fixed Income |
52-Week High | $87.26 | $84.82 |
52-Week Low | $34.31 | $81.07 |
Enterprise Value | $10.88B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.42, up 0.17% over 24 hours. The technical outlook is neutral with bearish moving averages, while recent news highlights its low 0.03% expense ratio and competitive yield. Dividend distributions are scheduled through mid-2026, providing steady income.
The ETF offers a balance of yield and moderate risk through investment-grade corporate bonds. Key risks include interest rate sensitivity and economic volatility. Analyst sentiment is mixed, emphasizing cost efficiency but cautioning on duration exposure in a shifting rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
